# E-DRUG: Bamako Initiative (cont'd)

**URL:** <https://talk.edrugplus.org/t/e-drug-bamako-initiative-contd/4583>\
**Category:** e-drug\
**Created:** [March 5, 1999, 5:10am UTC](https://talk.edrugplus.org/t/e-drug-bamako-initiative-contd/4583 "1999-03-05T05:10:09Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![Kathleen\_Holloway](https://avatars.discourse-cdn.com/v4/letter/k/a587f6/32.png) [@Kathleen\_Holloway](https://talk.edrugplus.org/u/Kathleen_Holloway)\
**Post date:** [March 5, 1999, 5:10am UTC](https://talk.edrugplus.org/t/e-drug-bamako-initiative-contd/4583/1 "1999-03-05T05:10:09Z")

</div>

E-drug: Bamako Initiative (cont'd)  
---------------------------------------------

Dear Michel and other e-druggers,

I and many others will be very interested to hear the output from the  
Bamako Initiative conference next week. Will it be possible to arrange  
for a summary to be distributed on e-drug? I worked for a number of  
years in Nepal on revolving drug funds with the Britain Nepal Medical  
Trust (BNMT) and am now completing a PhD investigating the effects  
of different charging mechanisms (types of user fee) on the quality  
and cost of prescribing in rural Nepal.

In a WHO workshop (Financing essential drugs: report of a WHO  
workshop, WHO/DAP/88.10 ), it was expressed that certain kinds of  
user fee may encourage irrational drug use and that potentially 50% of  
drug costs could be saved by rational prescribing. Despite this, few  
studies have examined the relationship between user fee type and  
prescribing quality or estimated the cost of irrational prescribing. In  
Nepal we found that changing the user fee from a fee per prescription  
to a fee per drug item (covering a full course) was associated with an  
improvement in prescribing quality of 10-20% and a reduction in the  
average drug cost per prescription of over 30%. Such changes in  
prescribing quality and cost are of enormous importance both with  
regard to patient treatment and sustainability of any revolving drug  
funds.

I would be very interested to hear of the experience of any of the  
conference participants with regard to user fees and their effect on  
the quality and cost of prescribing. I completely agree with the  
questions posed by Michel and Jerome and would like to share some  
of the experience in Nepal, maybe raising more questions and  
stimulating discussion.

1. Equity  
In the revolving drug funds run by BNMT, the user fees were set at a  
level such that the average patient paid the equivalent to 25-30% of  
the average household cash income for a prescription containing two  
drugs. This level is much lower than that reported in many countries,  
yet the most disadvantaged section of the population was not using  
the health facilities. The cost of attending the health facility (in terms  
of travel, lost working time, etc) and the poor quality of care (all  
aspects, not just drug availability) have been cited by villagers in  
Nepal and many other countries as reasons for non-use. How are  
Bamako Initiative projects addressing this?

2. Quality of Care  
Prescribing health staff were absent from the health posts 20-40% of  
the time and all aspects of quality of care (diagnosis, dispensing,  
syringe/needle sterilization) were low in the Nepali districts where  
BNMT operated its drug schemes. We also found that 30-50% of drug  
costs were 'wasted' through irrational prescribing and that 30% of  
patients did not know their dosing schedules immediately on exiting  
the health facilities. Using the WHO/INRUD core indicators, the quality  
of care (prescribing and non-prescribing) found in Nepal was similar to  
that seen in many developing countries. In this context, without  
addressing these other aspects of care, what does the provision and  
financing of drugs achieve?

3. Supervision and sustainability  
BNMT provided human resources and finance to supervise the running  
of the revolving drug funds. Thus it was ensured that the majority of  
patients paid the fees they were supposed to pay, and about 90% of  
expected moneys were collected, all these moneys being used to  
purchase more essential drugs. However, it has been shown in Nepal  
and elsewhere that without such supervision patients often do not pay  
the fees they are supposed to (inappropriate exemptions and  
non-exemptions, and extra unofficial fees) and often money and drugs  
'disappear'. Also, the money may not be collected or not used to  
purchase more drugs. All these things affect cost-recovery. In Nepal  
the local communities and government are a long way from being able  
to deal with these issues. How are these things managed in Bamako  
Initiative projects? Are they even monitored? In many projects they are  
not.

I would be very interested to hear of sustainable success stories with  
regard to the Bamako Initiative. However, unless the above questions  
are addressed, I do not think that a judgement can be made  
concerning any individual Bamako Initiative project. The mere  
presence of regular drug re-supply and reasonable cost recovery does  
not necessarily equate with success in terms of improved access to  
care of adequate quality.

Kathy Holloway,  
Former Drug Scheme Coordinator, BNMT.  
Temporary Address: 19 Camden Mews, London NW1 9DB, UK.  
Tel: 00 44 171 482 1919  
e-mail: k.a.holloway@sbu.ac.uk  
--  
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.  
Mail administrative requests to `majordomo@usa.healthnet.org'.  
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.
